Synopsis
Reduce vaso-occlusion, organ damage and infection through coordinated surveillance, hydroxycarbamide and preventive care while supporting reproduction, transition, mental health and shared self-management.
- Sickle-cell disease is a lifelong multisystem disorder; absence of recent pain admissions does not exclude progressive renal, pulmonary, neurological, retinal or skeletal injury.
- Every patient should have named specialist follow-up, an individual acute-pain plan, primary-care coordination and a record of genotype, baseline haemoglobin and transfusion antibodies.
- Hydroxycarbamide increases fetal haemoglobin and reduces painful crises and acute chest syndrome; offer it through shared specialist discussion when benefits fit the clinical phenotype.
Key red flags
New hypoxia, focal neurology, sustained priapism or fever exceeds routine long-term review and activates emergency care.
Investigation priorities
Establish steady-state anaemia, marrow response and treatment toxicity.
Management branches
A person with sickle-cell disease attends scheduled specialist follow-up.
- Reconcile genotype, baseline haematology, admissions, transfusions, antibodies, medicines, vaccines and the individual emergency plan with patient-held information.
- Assess renal, hepatic, cardiopulmonary, neurological, retinal, musculoskeletal, sexual and mental-health domains using age-appropriate tests and symptom triggers.
Key medicines
HydroxycarbamideSpecialists commonly begin at 15 mg/kg orally once daily, reduce the starting dose in renal impairment and titrate in small steps against counts, tolerance and clinical response to a maximum tolerated dose, usually not exceeding 35 mg/kg/day.
Phenoxymethylpenicillin prophylaxisUse the current age- and risk-based sickle or asplenia protocol, commonly 250 mg orally twice daily in adults when ongoing prophylaxis is indicated, with an allergy alternative.